Evidence map›Paper›PMID 40759652›Full record

ArticleNature communications2025

Defective Olfactomedin-2 connects adipocyte dysfunction to obesity.

Aina Lluch, Jèssica Latorre, Isabel Espadas, Núria Oliveras-Cañellas, José M Moreno-Navarrete, Estefanía Caballano-Infantes, Gitalee Sarker, Nicolás F Malvido, Pablo Garrido-Gil, José L Labandeira-García and 18 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Olfactomedin-2 at the Crossroads of Smooth Muscle Cell Plasticity.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Aina LluchService of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.ORCID http://orcid.org/0000-0003-4216-4436
Jèssica LatorreService of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
Isabel EspadasCentro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Consejo Superior de Investigaciones Científicas (CSIC), University Pablo de Olavide, Seville, Spain.ORCID http://orcid.org/0000-0002-9811-9717
Núria Oliveras-CañellasService of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.ORCID http://orcid.org/0000-0002-7758-3326
José M Moreno-NavarreteService of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.ORCID http://orcid.org/0000-0002-2883-511X
Estefanía Caballano-InfantesService of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.ORCID http://orcid.org/0000-0001-8269-9158
Gitalee SarkerDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2175-8705
Nicolás F MalvidoDepartment of Physiology, CiMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Pablo Garrido-GilInstituto de Investigación Sanitaria de Santiago de Compostela (IDIS), CiMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0001-7734-8783
José L Labandeira-GarcíaInstituto de Investigación Sanitaria de Santiago de Compostela (IDIS), CiMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Naoki NakayaSection on Retinal Ganglion Cell Biology, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2200-5200
Silvia MoraDepartment of Biochemistry and Molecular Biomedicine, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8473-1497
Eduardo ChicanoDepartment of Cell Biology, Physiology and Immunology, Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC), University of Cordoba, Reina Sofia University Hospital, Córdoba, Spain.
Jaime López-AlcaláDepartment of Cell Biology, Physiology and Immunology, Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC), University of Cordoba, Reina Sofia University Hospital, Córdoba, Spain.
María M MalagónCIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0002-2419-2727
Alejandro Martín-MontalvoCentro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Consejo Superior de Investigaciones Científicas (CSIC), University Pablo de Olavide, Seville, Spain.ORCID http://orcid.org/0000-0002-3886-5355
Birong ZhangSystems Immunity Research Institute, Cardiff University, Cardiff, UK.
You ZhouSystems Immunity Research Institute, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0002-1743-1291
Ana I DomingosDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-7938-4814
Miguel LópezCIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0002-7823-1648
Johanna PörschkeInstitute for Tumor Immunology, Center for Tumor Biology and Immunology, Philipps University, Marburg, Germany.
María Gómez-SerranoInstitute for Tumor Immunology, Center for Tumor Biology and Immunology, Philipps University, Marburg, Germany.ORCID http://orcid.org/0000-0002-9669-091X
Witold SzymanskiInstitute of Translational Proteomics & Core Facility Translational Proteomics, Biochemical/Pharmacological Centre, Philipps University, Marburg, Germany.ORCID http://orcid.org/0000-0002-1202-3299
Johannes GraumannInstitute of Translational Proteomics & Core Facility Translational Proteomics, Biochemical/Pharmacological Centre, Philipps University, Marburg, Germany.ORCID http://orcid.org/0000-0002-3015-5850
Stanislav I TomarevSection on Retinal Ganglion Cell Biology, Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3042-8502
Ismael González-GarcíaCIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0002-5545-5841
José M Fernández-RealService of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.ORCID http://orcid.org/0000-0002-7442-9323
Francisco J OrtegaService of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain. fortega@idibgi.org.ORCID http://orcid.org/0000-0003-2111-769X

Funding

Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CP19/00109Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI21/00074
6 · The paper itself

Abstract

Olfactomedin-2 (OLFM2) is a pleiotropic glycoprotein emerging as a regulator of energy homeostasis. We here show the expression of OLFM2 to be adipocyte-specific and inversely associated with obesity. OLFM2 levels increase during adipogenesis and are suppressed in inflamed adipocytes. Functionally, OLFM2 deficiency impairs adipocyte differentiation, while its over-production enhances the adipogenic transformation of fat cell progenitors. Loss and gain of function experiments revealed that OLFM2 modulates key metabolic and structural pathways, including PPAR signaling, citrate cycle, fatty acid degradation, axon guidance and focal adhesion in 3T3 cell lines and primary human adipocytes. On the molecular level, OLFM2 deficiency in differentiated adipocytes predominantly downregulates genes involved in cell cycle. Extending these findings in vivo, both whole-body Olfm2 knockout and adipose-specific Olfm2 depletion in mice resulted in impaired adipose cell cycle gene expression, with the latter also displaying fat mass accretion and metabolic dysfunction. Collectively, our results underscore a critical role for OLFM2 in adipocyte biology, and support a causative link between reduced adipose OLFM2 and the pathophysiology of obesity.

Indexed as

AdipocytesExtracellular Matrix ProteinsGlycoproteinsObesity3T3-L1 CellsAdipogenesisAdipose TissueAnimalsCell CycleCell DifferentiationFemaleHumansMaleMiceMice, Inbred C57BLMice, KnockoutExtracellular Matrix ProteinsGlycoproteinsolfactomedin

Identifiers

PMID40759652
PMCPMC12322249

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.